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A B S T R A C T
Purpose: The Wada test is still the gold standard procedure to predict language and memory deﬁcits
before temporal lobe epilepsy surgery. As amobarbital was no longer available, our aim was to validate
propofol as an alternative.
Method: We retrospectively studied 47 patients who underwent a bilateral intracarotid procedure,
performed with amobarbital (18), or propofol (29), between 2000 and 2010 during the preoperative
evaluation of temporal lobe epilepsy.
Results: The number of patients experiencing an adverse event (mostly transient disturbance of
consciousness or benign ocular symptoms) during both injections did not differ signiﬁcantly between
amobarbital and propofol. Hemispheric dominance was successfully determined in 96.5% patients with
propofol vs. 94.4% with amobarbital for language, and in 72.4% under propofol vs. 77.7% under
amobarbital for memory with no signiﬁcant difference between groups.
Conclusion: Propofol can be used for the Wada test with an efﬁcacy and safety comparable to
amobarbital.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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The Wada test traditionally consists of a selective intracarotid
injection of a fast acting barbiturate drug, generally sodium
amobarbital, which transiently inhibits the ipsilateral cerebral
hemisphere, in order to isolate the contralateral hemisphere and
assess its activity. The original aim of this intracarotid procedure
(ICP) developed by Dr Jung Wada in 19601 was to conﬁrm the
hemispheric lateralization of speech during preoperative evalua-
tion of some refractory epilepsies in order to predict a risk of
aphasic sequela. The test was extended to the study of hemispheric
localization of memory functions, especially before considering
anterior temporal lobectomy, in order to prevent the risk of global
amnesic syndrome as in patient HM.
Nowadays, the traditional Wada test needs to be re-evaluated
because amobarbital is no longer available in many countries3 and
other anesthetic drugs with different pharmacokinetic character-
istics are currently used.4* Corresponding author at: CERCO – Centre de Recherche Cerveau et Cognition
UMR 5549, Pavillon Baudot, CHU Toulouse, Hoˆpital Purpan, Place du Dr Baylac,
31059 Toulouse, France. Tel.: +33 06 78 93 33 84.
E-mail address: curot@cerco.ups-tlse.fr (J. Curot).
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http://dx.doi.org/10.1016/j.seizure.2013.10.009There is still no consensus on a single substitute for amobarbi-
tal. One of the most widely used alternatives is propofol. Bazin and
colleagues5were the ﬁrst to describe the use of propofol to perform
ICP and propofol ICP has now been reported in several studies,6–10
where it appears to be as effective and well tolerated as the
amobarbital procedure.
In 2004, 12 propofol ICP were compared to 55 amobarbital ICP.7
ICP was successfully performed for language in 12 patients and for
memory in 9 with propofol, in comparison to 52 language
lateralization and 41 conclusive memory assessments using
amobarbital. Only minor adverse effects (AE) were observed
(laughing in one patient, and head and eye version in another).
In 2005 a study evaluated all AE, apart from the well-known
cardiovascular effects, induced by intravenous propofol injection8
during ICP in 58 patients and proposed a classiﬁcation of AE in
three severity grades (see Fig. 1). AE were reported for one third of
patients with propofol. Magee et al.10 recently reported AE in 29.1%
of unilateral propofol ICP with no signiﬁcant differences in number
and type of AE compared with amobarbital.
Nevertheless it is difﬁcult to draw deﬁnitive conclusions from
these studies because of the small number of patients (at most 25
propofol ICP9), the heterogeneity of affections (only a speciﬁc
cohort of epileptic patients10) and absence of standardizedvier Ltd. All rights reserved.
Fig. 1. AE considering all ICP, according to classiﬁcation adapted from Mikuni et al.8 ns: non signiﬁcant. *The following AE were already described in Mikuni et al.’s
classiﬁcation8: eye pain, lacrimation, face contortion, shivering laughing and apathy (grade 1), confusion, head and eye version and involuntary movements (grade 2),
increased muscle tone with twitching and rhythmic movements or tonic posture (grade 3). We added symptoms not reported in Mikuni’s study: headache, sweats and warm
feeling (grade 1), tremor (grade 2), disturbance of consciousness, and signiﬁcant arterial hypotension or hypertension (grade 3). Grade 1 symptoms: we observed no
signiﬁcant difference between amobarbital and propofol during ﬁrst (x21 ¼ 0:721, p = 0.396), second (x21 ¼ 2:715, p = 0.099) or both injections (x21 ¼ 3:118, p = 0.077). Grade 2
symptoms: we observed no signiﬁcant difference between amobarbital and propofol during ﬁrst injections (x21 ¼ 0:033, p = 0.855). No grade 2 symptoms were observed
during second injections with either drug. Grade 3 symptoms: we observed no signiﬁcant difference between amobarbital and propofol during ﬁrst (x21 ¼ 0:033, p = 0.880),
second (x21 ¼ 0:559, p = 0.455) or both injections (x21 ¼ 0:146, p = 0.702).
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only one unilateral ICP is usually performed, although it has been
demonstrated that bilateral ICP has a better prognostic value in
predicting both post-operative verbal memory and verbal intelli-
gence quotient.11
For all these reasons, standardization and validation of propofol
use are needed, especially in bilateral ICP. We sought to contribute to
this by retrospectively reviewing the complete series of epileptic
adult patients who underwent ICP in our center. Our purpose was to
make a detailed comparison of the technical characteristics and
tolerance of bilateral ICP with propofol and amobarbital. We are
aware that noninvasive techniques are currently being developed
with the potential effect of making the Wada test obsolete.12,13
Despite this context, we are convinced that ICP still has indications
and that it is important to discuss which drug to use for the
procedure.
2. Method
2.1. Population
We retrospectively reviewed all data from 51 patients (26
women) aged 18–57 years (mean age = 34.6  10), who had
undergone an ICP between 2000 and 2010 during preoperative
evaluation of refractory epilepsy at the University Hospital of Toulouse,
France. All patients had a comprehensive assessment, including
neurological examination, neuropsychological testing, routine MRI,
surface EEG and video. ICP was carried out as part of the patients’
clinical care. Each patient received detailed information about the
objectives and course of the procedure, and gave informed consent in
the usual way.
We used amobarbital in 18 patients (from 2000 to 2003), then,
at the beginning of the shortage of amobarbital in France,
methohexital in 3 patients (2003). We very quickly stopped using
methohexital because duration of action of the drug was too short,
and propofol has been employed since then. Thirty patients have
had propofol ICPs since 2004.
2.2. Procedure
Selective catheterization of the internal carotid artery (ICA) was
performed by an interventional neuroradiologist (PT or MK), using a
transfemoral approach. An angiography of the intracranial circula-
tion was performed before each anesthetic injection to study its
distribution territory. Selective ICA anesthesia was performed with
the same procedure for both sides in each patient. The cerebral
hemisphere to be operated on was ﬁrst anesthetized. Blood pressure,
heart rate and oxygen saturation were monitored non-invasivelythroughout the procedure. EEG recording (sampled at 256 Hz,
bipolar montage, 10 channels, reference between Cz and Pz
electrodes), started several minutes before the anesthetic injection
and continued several minutes after the return of baseline clinical
and EEG signs. It was read on line by an electroencephalographer
(MD or LV). Before injection, a baseline state was obtained for EEG,
visual ﬁelds, hand strength and cognitive functions. Patients were
instructed to maintain arms and hands up, and to count aloud. While
they counted to ten, the anesthetic solution was slowly injected
manually through the catheter directly into the ICA (see Table 2). The
injection was stopped when effective anesthesia was conﬁrmed, as
soon as hemiparesis was observed. Hand strength, sensitivity, visual
ﬁeld and language were evaluated periodically before the start of the
test, after every minute and at the end of the test. A memory
retention test was done after recovery had been veriﬁed through
complete normalization of EEG and a neurological examination. The
second hemisphere was evaluated about 30 min after the ﬁrst.
2.3. Neuropsychological assessment
All patients underwent neuropsychological testing before ICP to
determine the appropriate level of difﬁculty for the items of the
test. The dominant hemisphere for language was determined by
the onset of language impairment (speech arrest, dysphasia, delay
in understanding and producing comprehensible language) after
drug injection into one side but not the other. Speech control was
deﬁned as bilateral if language impairment occurred after injection
of both sides, and was not deﬁned when no language impairment
occurred after injection of both sides.
Memory assessment began approximately 1 min after injection,
as soon as anesthesia was both effective and allowed sufﬁcient
cooperation from the patient. Memory items were presented in
three consecutive parts, in the same order in each part and for each
patient (who was instructed to repeat, read or name every item and
to memorize them) to assess verbal and nonverbal episodic
memory: 3 audio presented words, 3 abstract Figure 3 written
words, 3 concrete pictures, a sentence, and two real objects. The
memory retention test began 5–10 min after clinical examination
and EEG had returned to baseline, usually 10–15 min after the
injection.
Free recall and recognition memory were tested by using a
three-alternative forced-choice task. Total memory score was
obtained by adding one point for each item with good retrieval. An
asymmetry score was calculated by subtracting the memory score
of the pathological hemisphere from the memory score of the
contralateral hemisphere. One hemisphere was considered domi-
nant when there was a gap of more than two points between the
total memory scores of the two hemispheres.
Fig. 2. Details of main adverse events in both groups considering all ICP. ns: non-
signiﬁcant (p > 0.05). 1 – Ocular symptoms included eye pain (intraocular or
retroocular), lacrimation, itching, ﬂashes. 2 – Disturbance of consciousness:
occurred in 7 injections with propofol (mild and brief loss of contact (5 injections),
moderate drowsiness lasting 140 s (1 injection) and snoring followed by crying and
agitation (1 injection), vs. 8 injections with amobarbital, among which 3 deep
drowsiness (2 lasting 120 and 160 s, and 1 shorter followed by agitation). 3 –
Movement disorders were contralateral upper limb dystonic attitudes (propofol:
1.7% vs. amobarbital: 2.8% of injections), axial dystonia (propofol: 5.1% vs.
amobarbital: 5.6% of injections), trismus (propofol: 0, vs. amorbarbital: 8.3% of
injections) and tremor (propofol 1, vs. amobarbital 0 injection). 4 – Autonomic signs
included cold or warm feelings in the head, chills, sweats, hypotension (n = 1), and a
marked hypertension (193/87 mmHg peak) during both injections in 1 patient with
chronic hypertension). 5 – Mood disorders included mild euphoria in 3 patients
with propofol. They did not disrupt ICP and accurate lateralization for memory and
language were obtained for two of the patients. 6 – Headache was observed in 1
patient with propofol. One patient complained about left earache and tingling on
the forehead; this occurred during a left injection with poor ICA distribution and
reﬂux in the external carotid artery. As a third injection was necessary for successful
assessment of the left hemisphere we excluded this patient from analysis.
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We considered any AE that could endanger the patient
(hemodynamic and vegetative disorders), create discomfort (pain,
dysphoria), or hinder the realization of the test (motor disorders
and disturbance of consciousness (DoC)). We detailed all AEs
(Fig. 2) and rated their severity using Mikuni’s classiﬁcation,8
adapted for symptoms not reported in his study (Fig. 1).
2.5. Statistical analyses
Comparison of continuous data (i.e. duration of EEG slowing)
was computed for each group (amobarbital and propofol) with a
univariate ANOVA. Categorical data (i.e. occurrence of an AE) were
analyzed using the x2 test. Non-parametric tests (Mann Whitney U
test) were used to compare doses of each drug that led or did not
lead to DoC, because of substantial asymmetry in the sizes of the
groups. A p value  0.05 was considered as the signiﬁcance
threshold for considering groups as different. In one patient in the
propofol group, no deﬁcit or EEG slowing was observed during the
ﬁrst injection on the left side. As a third injection was necessary for
successful assessment of the left hemisphere we excluded this
patient from the analysis. We excluded methohexital procedures
from the statistical analyses in order to dichotomize the sample
into propofol vs. amobarbital.
3. Results
3.1. Patients
Twenty-nine patients tested with propofol and 18 with
amobarbital were analyzed. Demographic or clinical character-
istics did not differ signiﬁcantly between groups (Table 1).3.2. Tolerance (Figs. 1 and 2)
AEs were observed during 38 ICP in 27 patients (57.4%) of the
full sample. All AEs were transient and occurred only during the
procedure. We observed AEs in 8 of the 18 patients tested with
amobarbital (44.4%) vs. 19 of the 29 with propofol (65.5%). There
was no statistical difference between groups (x21 ¼ 2:018,
p = 0.155). AEs were observed in 12 out of 36 amobarbital
(33.3%) vs. 26 out of 58 propofol injections (44.8%), without
statistical difference between groups considering all AEs
(x21 ¼ 1:219, p = 0.270). Furthermore, the number of patients with
an AE during the ﬁrst (x21 ¼ 0:735, p = 0.391) and second injections
(x21 ¼ 0:510, p = 0.475) did not differ signiﬁcantly between groups.
The two main AEs observed in both groups were DoC and ocular
disorders.
3.3. Disturbance of consciousness (DoC)
Level of DoC varied from mild sedation to deep drowsiness. DoC
(mostly mild brief loss of contact) was observed in 7 out of 58
propofol injections (12.1%) with similar incidence in ﬁrst and
second injections. With amobarbital, DoC were more severe and
more frequent (8 out of 36 injections, 22.2%), and DoC was more
frequent during the second injection. However, the number of
patients with DoC did not differ signiﬁcantly between the two
groups for ﬁrst (x21 ¼ 1:403, p = 0.236) or second injection
(x21 ¼ 1:236, p = 0.266). All symptoms returned to normal at the
end of the procedure. No patient required intensive care. DoC was
always associated with the existence of an anterior or posterior
communicating artery (PCA), in support of rapid extension of the
drug distribution in the brain. Anesthetic doses tended to be higher
in ICP with DoC than in procedures without, for both drugs, but the
difference was not statistically signiﬁcant (propofol: 17.2  12.4,
vs. 12.1  2.9 mg, p = 0.415; amobarbital: 128.7  17.2, vs.
119.2  12.1 mg, p = 0.118).
3.4. Ocular symptoms
Mostly ipsilateral to the injection, and always transient, ocular
symptoms usually appeared a few seconds after injection and
could last for up to 1 min. They predominated with propofol,
mostly during the second injection: 8 out of 58 injections (13.7%)
with propofol, vs. 3 out of 36 (8.3%) with amobarbital, but without
signiﬁcant difference (x21 ¼ 0:637, p = 0.425). Bilateral glare
illusions were noticed and were always associated with a PCA.
3.5. Other AEs
Considering all injections, movement and dystonic disorders
were as frequent with amobarbital (n = 4; 11.1%) as with propofol
(n = 7; 12%), (x21 ¼ 0:02, p = 0.582). Pain, mood disorders, and
autonomic disorders were only noted with propofol. One propofol
injection was accompanied by an increase of epileptic paroxysms
on EEG.
There was no signiﬁcant difference between amobarbital and
propofol groups for grade 1, grade 2, and grade 3 symptoms during
ﬁrst and second injections.
3.6. Technical characteristics of injections (Tables 2 and 3)
The ﬁrst side injected was always the hemisphere including the
epileptogenic focus. The delay between ﬁrst and second injections
was similar in both groups (amobarbital: 30.4  5.3, propofol:
35.3  5.7 min). There was no statistical difference between the two
groups for duration of slowing EEG (F1,45 = 0.019, p = 0.891), delay of
onset of hemiparesis (F1,34 = 2.509, p = 0.122), or duration of
Table 1
Demographic, clinical and anatomical characteristics of patients in amobarbital and propofol groups.
Anesthetic Amobarbital Propofol Statistics p value
Patient (number) 18 29 – –
Sex
Men 7 (39%) 17 (58.6%) x21 ¼ 1:73 0.198
Women 11 (61%) 12 (41.3%)
Age (yo. mean  SD) 37  7 32  10 F1,46 = 2.551 0.117
Epileptogenic zone side
Right 10 (56%) 16 (55.1%) x21 ¼ 0:065 0.798
Left 8 (44%) 13 (44.8%)
Epileptogenic zoneb
Temporal 17 (94.4%) 29 (100%)
Frontal 0 0 – –
Fronto-temporal 1 0
Etiology of epilepsyc
HS 14 (77.8%) 20 (68.9%) x21 ¼ 0:431 0.511
Cavernomas 2 1
Tumors 1 (DNET) 1 (ganglioglioma)
Others 1 arachnoid cyst 4 MCD
1 sequelae of craniopharyngioma surgery
2 cryptogenic
Handednessa
Right 12 (67%) 21 (72.4%) x21 ¼ 1:59 0.452
Left 6 (33%) 6 (20.6%)
Bilateral 2 (6.8%)
Language lateralization
Right 3 (16.7%) 3 (10.3%) x21 ¼ 1:043 0.594
Left 14 (77.8%) 25 (86.2%)
Undetermined or bilateral 1 1
Memory lateralization
Right 7 (38.9%) 8 (27.5%) x21 ¼ 0:345 0.557
Left 7 (38.9%) 13 (44.8%)
Undetermined or bilateral 2 8
a Handedness was assessed as right, left or bilateral with Edinburgh Manual Dominance Questionnaire (Oldﬁeld, 1971).
b 28 patients in propofol group, and 17 in amobarbital group suffered from a pure temporal lobe epilepsy, mainly mesial temporal. Two patients whose epileptogenic zone
extended beyond temporal lobe limits were included. One patient in propofol group suffered from a frontal lobe epilepsy.
c Etiology was mostly hippocampal sclerosis (HS). DNET: Dysembryoplastic neuroepithelial tumor. MCD: Malformations of cortical development: 3 meningoencepha-
locele, 1 focal cortical dysplasia, 1 undetermined lesion.
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(ﬁrst or second injection) had no effect on delay of hemiparesis onset
(F1,34 = 1.111, p = 0.299), duration of hemiparesis (F1,39 = 0.524,
p = 0.473), or duration of EEG slowing (F1,45 = 0.441, p = 0.51). Thus
no predominant inhibitory effect of amobarbital or propofol on motor
functions was observed. Procedure duration was slightly, but notTable 2
Comparison of characteristics of procedures with amobarbital and propofol between ﬁ
Amobarbital
1st injection
Dose (M  SD, mg)a 120  14.5c
Delay of onset of hemiparesis from injection (M  SD, s) 37  39 
Duration of hemiparesis (M  SD, s) 283  147 
Duration of EEG slowing (M  SD, s) 420  100 
Duration of test (M  SD, s) 301  123 
Homonymous hemianopia (% of patients in each group) 38.8% 
Visualization of an ACA artery (%)d 61.1% 
Visualization of a PCA (%)e 77.7% 
M  SD: mean  standard deviation.
a Both drugs were slowly injected in about 10 s. Injection stopped when effective anest
b Propofol was dispensed at the concentration of 10 mg/ml. Dilution of propofol consis
1.5 mg per 6 ml of saline for the other patients (since 2005). Two patients received tw
c Amobarbital was injected at a concentration of 20 mg/ml.
The dose of product did not differ signiﬁcantly between both injections, neither in the am
d ACA: anterior communicating artery. No signiﬁcant difference was observed between
(x21 ¼ 0:865, p = 0.352) in visualization of an ACA.
e PCA: posterior communicating artery. No signiﬁcant difference was observed betwee
(x21 ¼ 0:431, p = 0.511) in visualization of a PCA.signiﬁcantly, shorter with propofol (278  106 vs. 306  114 s with
amobarbital; F1,45 = 0.621, p = 0.435). The order of injection had no
effect on procedure duration (F1,45 = 0, p = 0.994).
We also compared the drug’s effect according to the side of
injection (Table 3). No signiﬁcant difference was observed between
propofol and amobarbital groups concerning doses, AE, delay ofrst and second injections.
Propofol
1st injection
Amobarbital
2nd injection
Propofol
2nd injection
13.75  6.4b 122.8  13.2 12  3b
27  9 27  25 28  13
342  254 301  127 286  138
431  203 478  157 417  130
290  150 311  108 279  105
66.6% 27.7% 53.3%
62% 55.5% 68.9%
77.7% 86.2% 68.9%
hesia was conﬁrmed by the onset of a controlateral facial and upper extremity palsy.
ted in 1.5 mg in 1.5 ml of saline serum for 8 patients (between 2004 and 2005) and in
o different doses in the left and right ICP.
obarbital (F1,17 = 0.702, p = 0.414), nor in the propofol group (F1,29 = 2.661, p = 0.114).
 amobarbital and propofol during ﬁrst (x21 ¼ 0:004, p = 0.948) and second injections
n amobarbital and propofol during ﬁrst (x21 ¼ 0:559, p = 0.455) and second injections
Table 3
Comparison of characteristics of procedures and main adverse events with amobarbital and propofol between left and right injections.
Left injections Right injections
Amobarbital Propofol p-value Amobarbital Propofol p-value
Delay of onset of hemiparesis from injection (M  SD, s) 38  39 27  10 0.143 25  26 28  13 0.636
Duration of hemiparesis (M  SD, s) 290  138 357  229 0.305 292  139 268  170 0.641
Duration of EEG slowing (M  SD, s) 266  108 293  189 0.578 248  108 230  122 0.622
Duration of test (M  SD, s) 319  91 311  150 0.841 293  135 257  95 0.288
Homonymous hemianopia (number (%) of injections) 4 (22.2%) 20 (68.9%) 0.003 9 (50%) 16 (55.2%) 0.635
Visualization of an ACAa (number (%) of injections) 11 (61.1%) 20 (68.9%) 0.581 10 (55.5%) 18 (62%) 0.658
Visualization of a PCAb (number (%) of injections) 13 (72.2%) 24 (82.7%) 0.391 15 (83.3%) 21 (72.4%) 0.390
Adverse eventsc (number (%) of injections)
Ocular disorders 0 (0%) 3 (10.3%) 0.158 3 (16.6%) 7 (24.9%) 0.504
Movement disorders 3 (16.6%) 2 (6.8%) 0.291 0 (0%) 4 (13.7%) 0.320
Disturbance of consciousness 4 (22.2%) 5 (17.2%) 0.673 4 (22.2%) 2 (6.8%) 0.126
Adverse eventsd (number (%) of injections)
Grade 1 0 5 (17.2%) 0.077 3 (16.6%) 8 (27.5%) 0.312
Grade 2 1 (5.5%) 1 (3.4%) 0.624 0 1 (3.4%) 0.617
Grade 3 4 (22.2%) 7 (24.9%) 0.586 4 (22.2%) 3 (10.3%) 0.358
M  SD: mean  standard deviation.
a Anterior communicating artery.
b Posterior communicating artery.
c Details in Fig. 2.
d Adverse events: according to the classiﬁcation adapted from Mikuni et al.8 and detailed in Fig. 1.
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or test duration, for left and for right injections. Transient
homonymous hemianopia was more frequent with propofol
injections (62%) than with amobarbital (33.3%), (ﬁrst injection:
x21 ¼ 4:762, p = 0.029; second injection: x21 ¼ 2:371, p = 0.124). We
also noticed more homonymous hemianopia during left injections
with propofol than with amobarbital (x21 ¼ 8:852, p = 0.003).
Visual ﬁeld was difﬁcult to assess in 2 propofol injections, because
of a tonic head and eyes rotation.
3.7. Hemispherical dominance for language, and memory
Duration of language disorders was 471  230 s with propofol
vs. 385  194 with amobarbital, and was not signiﬁcantly different
between the two drugs either during the ﬁrst (F1,21 = 3.361, p = 0.082)
or second injection (F1,25 = 0.083, p = 0.776).
Problems that could impair ICP interpretation occurred during
14 injections with propofol in 12 patients, for technical reasons (5
injections) or severe AE.9 Technical problems were: anesthesia too
short (2 injections), different doses required for ﬁrst and second
injections,2 non-selective catheterism with injection partially in
the right common carotid.1 These events were not directly drug-
related. AE that could partially hinder neuropsychological assess-
ment were DoC (6 injections), exhilaration2 and hemineglect.1
Nevertheless, a deﬁnite lateralization could be given for language
in all tests and for memory in 8 of these 12 patients. We reported
potential interpretation artifacts during 9 amobarbital injections,
in 9 patients (50%), mostly related to excessive drowsiness.
Language was lateralized for 8 of them, and memory for 6.
Memory could be lateralized for 21 patients (72.4%) with
propofol and 14 (77.7%) with amobarbital, without statistical
difference between groups (x21 ¼ 0:046, p = 0.829). Hemispheric
dominance for language was obtained for 28 patients with
propofol (96.5%) and 17 (94.4%) with amobarbital.
4. Discussion
It is not always easy to compare our results with those
published previously because many variables can interfere.
According to the centers, ICP can be unilateral or bilateral, drug
doses are not the same, and the neuropsychological tests chosen
for evaluation can vary.4.1. A speciﬁc epileptic cohort
Indications of ICP are scarce and presurgical assessment for
epilepsy surgery remains the main indication. We included all the
epileptic patients who underwent an ICP in our center between
2000 and 2010, in order to obtain a large, homogeneous cohort
allowing the comparison of two groups of ICP, with propofol and
with amobarbital. In most previous studies, the interpretation of
the tolerance and efﬁcacy of drugs used for ICP could be biased by
the heterogeneity of the patients included.
A bilateral ICP was performed in all our patients, whereas only a
unilateral procedure was performed in certain other studies.10 In
our opinion, a bilateral procedure improves the assessment of
post-surgery memory outcome. Even if hippocampal reserve can
be evaluated by the hemispheric inhibition ipsilateral to the
seizure focus, a better prediction of post-operative verbal memory
and IQ, especially when the seizure focus is left-sided, has been
demonstrated with the bilateral procedure.11 In most studies
evaluating non-invasive techniques such as fMRI, the comparator
is bilateral ICP.22,25,28
4.2. Propofol is well tolerated
We performed comparisons between left and right injections as
done in previous works, and added comparisons between ﬁrst and
second injections, i.e. injection in the epileptogenic zone side
compared to the hemisphere considered as normal, a comparison
that has rarely been made in previous studies. One reason for
comparing the ﬁrst and second injections is to ensure the absence
of a cumulative effect of the products during the full procedure. In
our series, second propofol injections appeared to be as well
tolerated as the ﬁrst.
In accordance with previous studies, no lasting, disabling
propofol-related AE was recorded in our study. An AE was observed
in 33.3% of amobarbital injections vs. 44.8% of propofol injections,
without signiﬁcant statistical difference between groups. This
higher rate of AE in the propofol group than in the amobarbital
group was counterbalanced by the low grade of AE (mainly grade 1
according to Mikuni’s classiﬁcation). Our doses of propofol
(12.8  5.2 mg) were similar to those used by Mikuni (between 10
and 17 mg).8 In our study, 58 patients received propofol and 19
experienced an AE (33.3%): 7 (12%) patients experienced grade 3
J. Curot et al. / Seizure 23 (2014) 122–128 127symptoms, 6 grade 2 (10.3%) and 6 grade 1 (10.3%). In our series, grade
3 symptoms occurred in 11 injections (9 patients, 31%), grade 2 in 3
injections (3 patients, 10.3%) and grade 1 in 17 injections (12 patients,
41.3%). In most of our cases, AE were mild and short-lived,
disappeared before the end of the procedure and did not hinder
neuropsychological assessment. More severe AEs (grades 2 and 3)
were not more frequent with propofol than with amobarbital.
In Mikuni’s study,8 all the grade 3 symptoms consisted of
increased muscular tone with twitching or tonic posture. In our
series, we found no twitching but a similar rate of tonic postures
with propofol (3 of 29 patients) and most grade 3 symptoms were
DoC. Using this classiﬁcation, Magee et al.10 recently reported AE in
29.1% of unilateral propofol ICP (21.8% grade 1), with no signiﬁcant
differences with amobarbital in number and type of AE. Our results
are in agreement with these previous studies, stressing a majority
of grade 1 AE with propofol.
It is important to consider DoC because of its potential impact
on language and memory. DoC was not reported in Mikuni e tal.’s8
or Magee et al.’s10 works. In our cohort, DoC was observed with
both drugs, and was more intense with amobarbital. DoC had a low
impact on test feasibility. We did not ﬁnd any correlation between
propofol dose and the risk of DoC. Moreover, in Mikati’s study,9 no
sedation was noted and only one case of DoC, a confusion with
agitation, was reported although the total mean doses of propofol
were higher (59.6  40.9 mg), than those used in our series
(25.7  9.4 mg). In Mikuni’s study, an age older than 55 years, a
second dose greater than 10 mg and a total dose greater than 20 mg,
were signiﬁcantly correlated with grade 3 symptoms.8 None of our
patients was over 55 years of age, four experienced grade 3 symptoms
during the second injection, two of them had a second dose higher
than 10 mg and 3 had a total dose higher than 20 mg.
Transient euphoria was observed in our study only with
propofol and not with amobarbital. This AE was observed in 3
patients, independently of the site of injection (3 right and 1 left
injections). Laughing has already been reported in 2 patients
during a left injection.7 This transient euphoria may be the result of
a speciﬁc effect of the propofol molecule or due to a frontal
syndrome related to the anesthetic effect. The fact that euphoria is
not seen with amobarbital, which has anesthetic effects, pleads in
favor of a speciﬁc effect of propofol.
In one study,9 ocular symptoms occurred during injection in all
patients, whereas we did not observe this AE in a systematic way.
Ocular symptoms could be related to an action on cholinergic
transmission and vascular anastomosis between the ICA and
external carotid artery systems. In our study, ocular symptoms
occurred mainly when propofol was injected too rapidly. So, this
uncomfortable AE could be avoided by a slower injection of propofol.
To the best of our knowledge, concurrent EEG monitoring, as
done in our series, was performed in only one earlier study.9 In that
study, EEG slowing was observed to be ‘‘less remarkable and often
milder’’ with propofol than amobarbital, and one patient presented
a seizure with propofol. The high doses (59.6  40.9 mg) used in the
study may account for this event. In our series, we found an increase
in interictal epileptic activities in one patient but no seizure. No
increase of epileptic activities was observed in patients showing DoC.
4.3. Increasing tolerance of propofol in the future
With the increasing use of propofol in ICP, improving tolerance
has become a major concern. In one study, administration of
500 mg of intravenous methylprednisolone before propofol injec-
tion led to a signiﬁcant reduction of AE, with a decrease of 92% for
serious AE.14
Fujii et al. showed that injection of propofol in the middle
cerebral artery (MCA), may allow better tolerance,15 as mild DoC
occurred in only 6 of their 17 patients after MCA injection, while 3out of 4 presented moderate or severe DoC (one fell into a
reversible coma) after ICA injection. This indicates that a more
restricted site of injection could decrease the rate of severe AE.
However these results have to be modulated on account of the
small group of patients with ICA injection. In our larger population,
with similar doses of propofol, no coma was observed. It must also
be stressed that, although MCA injection is suitable for investigat-
ing language lateralization, exploration of memory requires ICA
injection due to the more extensive area of vascularization.
Finally, while Mikati et al.9 reported 70% of patients needing
more than one dose of propofol, we did not need a second injection
in most cases and most ICP gave satisfactory tests with a single
injection and low doses of propofol.
4.4. Propofol is as effective as amobarbital
Although the half-life of propofol is shorter than that of
amobarbital (2–24 vs. 14–42 h), propofol anesthesia enables a
complete neuropsychological assessment with no additional
technical constraint. The duration of the test was similar with
both drugs. A recent review summarizes various alternatives to
amobarbital ICP4: pentobarbital, propofol, methohexital and
etomidate, and notes that propofol appears to be the best. This
is consistent with our experience. We used methohexital in three
patients but this drug has such a short duration of action that
several injections were necessary and, in one patient, the test was
inconclusive in spite of reinjection of the product. Moreover
methohexital may signiﬁcantly increase seizure frequency com-
pared to amobarbital.16 Homonymous hemianopia, more frequent
in our patients with propofol than with amobarbital, may have led
to a bias when the cognitive task was performed. However, this AE
did not hinder the achievement of the test and was not a limiting
factor in the appreciation of the hemispherical dominance for
memory and language. We have no explanation other than a
possible historical measurement bias (amobarbital ICPs were
carried out before 2003, which could explain a difference in data
collection). This result should also be weighed against deeper
drowsiness with amobarbital, which could also be a limiting factor
for procedure achievement.
In Takayama’s study7 using propofol, language could be
lateralized in 12 and memory in 9 out of 12 patients vs.,
respectively, 52 and 41 out of 55 patients for amobarbital. There
was no statistical difference between propofol and amobarbital
groups for verbal and non-verbal responses. Our results are similar
in a larger and more speciﬁc population of epileptic patients: we
succeeded in ﬁnding language (96.5%) and memory (72.4%)
lateralization in a similar number of patients, with similar doses
of propofol. No statistical difference between verbal and visuo-
spatial memory scores was observed in our study. However
comparison with other studies is rendered difﬁcult by the
difference in the neuropsychological tests used.
4.5. Wada test will remain necessary
Research is currently attempting to develop non-invasive
techniques which will eventually lead to ICP being abandoned.17,18
Functional MRI (fMRI) is the most promising technique and has
already replaced ICP in a majority of patients for language
lateralization.19,20 Numerous studies have shown high concor-
dance for language lateralization between ICP and fMRI (about
90%) whatever the studies and the handedness of patients.
However, the reliability of fMRI for memory lateralization is
based on a small number of surveys.21–25 Nevertheless, Bonelli
et al.26 recently demonstrated, in a cohort of 72 patients, that fMRI
memory activation in the hippocampal regions was predictive of
both verbal and visual memory outcome after left or right anterior
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for memory assessment by multicentric studies and its clinical
application, the ICP test is currently necessary for predicting
postoperative selective memory deﬁcits in patients with atypical
memory assessment (absence of signiﬁcant memory impairment
before surgery, verbal and non-verbal memory deﬁcits, pre-
surgical unilateral memory deﬁcit). Moreover, ICP may still have an
indication in some refractory epileptic patients in whom fMRI is
contraindicated (pediatric patients, low IQ and pacemaker). A
recent retrospective analysis of 50 ICP27 listed its remaining
indications: non-compliance for fMRI task due to agitation, mental
disablement or perceptual impairment, and inconclusive language
activation mapping in fMRI, such as bilateral activation or atypical
lateralized activation pattern. This analysis found that fMRI data
were inconclusive or not feasible in 29 patients and, for 21 (72%) of
them, ICP could specify language lateralization.
5. Conclusion
As the Wada test will remain useful for some years in some
speciﬁc epileptic populations, discussing the characteristics of the
drugs used for this test and proposing a standardized procedure
across centers still remains a topic of interest. In conclusion,
propofol, despite its shorter half-life, allows a full, conclusive test
to be carried out with tolerance and performance equal to those of
amobarbital.
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